TargeGen Acquired By Sanofi-aventis
socalTECH
JUNE 30, 2010
San Diego-based TargeGen , a firm developing small molecule kinase inhibitors for the treatment of myelofibrosis (MF) and polycythemia vera (PV), has been acquired by Sanofi-aventis, in a deal worth as much as $560M, the firm said Wednesday. TargeGen had raised over $113M in venture funding from A.M.
140 
Let's personalize your content